Published in Gene Therapy Weekly, May 20th, 1996
The announcement was made by Thomas D'Alonzo, President and CEO of the company. The first phase of the Ad(GV)CD.10 trial will seek to evaluate the product's safety and anti-tumor effects.
GenVec is a developer of in vivo gene-based therapies and gene delivery systems for the treatment of acute and chronic diseases. In vivo genetic therapy permits the administration of corrective or therapeutic genes directly into affected tissues.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.